Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4R6S

Crystal structure of PPARgammma in complex with SR1663

Summary for 4R6S
Entry DOI10.2210/pdb4r6s/pdb
Related4R2U
DescriptorPeroxisome proliferator-activated receptor gamma, 4'-[(2,3-dimethyl-5-{[(1R)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid (3 entities in total)
Functional Keywordsnuclear receptor ligand binding domain, transcription
Biological sourceHomo sapiens (human)
Cellular locationNucleus: P37231
Total number of polymer chains2
Total formula weight64086.38
Authors
Marciano, D.P.,Griffin, P.R.,Bruning, J.B. (deposition date: 2014-08-26, release date: 2015-07-01, Last modification date: 2023-09-20)
Primary citationMarciano, D.P.,Kuruvilla, D.S.,Boregowda, S.V.,Asteian, A.,Hughes, T.S.,Garcia-Ordonez, R.,Corzo, C.A.,Khan, T.M.,Novick, S.J.,Park, H.,Kojetin, D.J.,Phinney, D.G.,Bruning, J.B.,Kamenecka, T.M.,Griffin, P.R.
Pharmacological repression of PPAR gamma promotes osteogenesis.
Nat Commun, 6:7443-7443, 2015
Cited by
PubMed Abstract: The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is the master regulator of adipogenesis and the pharmacological target of the thiazolidinedione (TZD) class of insulin sensitizers. Activation of PPARγ by TZDs promotes adipogenesis at the expense of osteoblast formation, contributing to their associated adverse effects on bone. Recently, we reported the development of PPARγ antagonist SR1664, designed to block the obesity-induced phosphorylation of serine 273 (S273) in the absence of classical agonism, to derive insulin-sensitizing efficacy with improved therapeutic index. Here we identify the structural mechanism by which SR1664 actively antagonizes PPARγ, and extend these findings to develop the inverse agonist SR2595. Treatment of isolated bone marrow-derived mesenchymal stem cells with SR2595 promotes induction of osteogenic differentiation. Together these results identify the structural determinants of ligand-mediated PPARγ repression, and suggest a therapeutic approach to promote bone formation.
PubMed: 26068133
DOI: 10.1038/ncomms8443
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.301 Å)
Structure validation

226707

數據於2024-10-30公開中

PDB statisticsPDBj update infoContact PDBjnumon